Aerie Pharmaceuticals, Inc.
COMBINATION THERAPY
Last updated:
Abstract:
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
Status:
Application
Type:
Utility
Filling date:
7 Dec 2021
Issue date:
24 Mar 2022